Pgiam/iStock via Getty Images Shares of PROCEPT BioRobotics ( NASDAQ: PRCT ) fell ~4% on Thursday after Jefferies launched the surgical robotics company with a Hold recommendation and $95 per share target, citing concerns over its valuation, Jefferies analyst Michael Sarcone wrote that PROCEPT, which markets the HYDROS.
Back to Health Page
